• June 3-6, 2024
  • San Diego Convention Center, California


Paul van der Horst

Paul van der Horst, PhD

Chief Business Officer
AgomAb Therapeutics
Paul van der Horst is Chief Business Officer at Agomab Therapeutics, where he is responsible for corporate development, corporate strategy, R&D portfolio strategy and budgeting, intellectual property and quality. Prior to Agomab, he was Head of Corporate Development at Galapagos NV (NASDAQ & Euronext: GLPG) from 2016-2021. In this role, he led all Galapagos’ major transactions, investments, licensing, and M&A activities. From 2013-2016, he worked at boutique investment bank Kempen & Co in Amsterdam, where he was responsible for broking and trading of European pharma & biotech stocks to institutional investors in Europe and the US. In his career, Paul has led the execution of over 20 buy and sell side pharmaceutical licensing and M&A transactions, ranging from research to late development stages, and has raised over USD1.5bn through private and public equity capital market transactions. Paul is Chairman of the Board of Directors at Molecure S.A. (WSE: MOC, Warsaw, Poland) and holds a PhD in Gynecological Oncology from the Erasmus University Medical Centre in Rotterdam, The Netherlands.
Speaking In


Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.